MeSH D003449 - cryoglobulinemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Roche | Ribavirin, Peginterferon alfa-2a | Pegasys Copegus | 2004-06-04 | |||
| Merck Sharp & Dohme | Ribavirin, Peginterferon alfa-2b | PegIntron/ Rebetol Combo Pack | 2008-06-13 |
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
38%3/8
Phase 3
57%4/7
Approved: 4Overall Success rate: 21%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use